Every cholesterol decision starts with the same question: how likely are you, specifically, to have a heart attack or stroke? The 2026 dyslipidemia guideline overhauls how that question gets answered — in two ways that matter enormously for anyone in mid-life trying to decide whether it's "time" for prevention therapy.
PREVENT: A New Calculator, and a 30-Year View
The guideline adopts the American Heart Association's PREVENT equations as the primary risk tool, replacing the older calculator used since 2013. PREVENT was built on data from millions of contemporary patients, incorporates kidney function and metabolic health, and — most importantly for younger adults — produces both a 10-year and a 30-year risk estimate.
The 30-year horizon changes conversations. A 42-year-old with an unimpressive 10-year risk of 4% may carry a 30-year risk north of 30% — a fundamentally different picture. Under the old framework, that patient was usually told to "keep an eye on it." Under the new one, that patient is exactly who the earlier and lower, for longer philosophy is aimed at: modest risk this decade, substantial risk over a lifetime, and decades of opportunity to change the trajectory.
Lower Thresholds for Starting Therapy
PREVENT feeds directly into treatment decisions, and the bar has moved. Lipid-lowering therapy can be considered at a 10-year risk of just 3–5%, and should be considered at 5–10% — categories that previous guidelines largely watched rather than treated. Combined with risk-enhancing factors (family history, inflammatory disease, adverse pregnancy history, elevated Lp(a)), far more adults in their 40s and 50s now warrant a real conversation about treatment.
Calcium Scoring: The Tiebreaker, Now With Top Billing
What about when the calculator says "intermediate" and you're genuinely unsure? The guideline's answer is coronary artery calcium (CAC) scoring — now elevated to a Class 1 recommendation, its strongest endorsement yet. A CAC scan is a quick, low-radiation CT that directly measures calcified plaque in your coronary arteries. It converts a statistical estimate into physical evidence:
- A score of zero in a lower-risk patient without diabetes, smoking, or a strong family history supports deferring medication — genuine reassurance, backed by data.
- A positive score means atherosclerosis is already present, and prevention shifts from "whether" to "how intensively."
Risk Assessment Is a Process, Not a Number
The new framework is layered by design: calculate PREVENT risk, weigh risk-enhancing factors, check Lp(a) at least once, and use calcium scoring when the decision is genuinely borderline. That is precisely how we practice at Cardiolucent — a comprehensive risk assessment that combines PREVENT-based estimates with coronary calcium scoring, advanced lipid testing, and in-office cardiac ultrasound, interpreted in one place by Dr. Kedan. It's also the backbone of our Executive Annual Cardiovascular Visit — one visit, a complete answer to the risk question.
Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia — a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, published in Circulation and the Journal of the American College of Cardiology, March 2026.